ERBB2 and breast carcinoma: Interestingly, the miRpower database could also provide survival analysis in certain subtypes and we found that high expression of miR‐4732‐5p was also associated with worse prognosis in ER+, PR+ and HER2+ patients (Figure 3B‐D), suggesting that miR‐4732‐5p may be a risk prognostic factor independent of breast cancer subtypes.